secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097582
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Q4 net loss $20.6M; cash $163.3M into 2028; key CRB-701/913 catalysts mid-2026
--------------------------------------------------------------------------------

- Q4 2025 net loss $20.6M ($1.25/share) vs $9.5M ($0.78) in Q4 2024; operating expenses rose to $22.0M.
- Cash $163.3M at Dec 31, 2025; extended runway into 2028 after $75M public offering in Q4.
- CRB-701 Phase 1/2 unconfirmed ORR: HNSCC 47.6%, cervical 37.5%; monotherapy data and FDA protocol discussions expected mid-2026.
- CRB-913 Phase 1a: 2.9% placebo-adjusted weight loss at 14 days; Phase 1b CANYON-1 (n=240) results due summer 2026.
- CRB-601 deprioritized; no further patient enrollment. Pipeline updates from ESMO 2025 and SITC 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526097582/0001193125-26-097582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526097582/crbp-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer